Can Regenerative Medicine Help Chronic Joint Pain?
PWritten by: Phil KimMedically reviewed by: Dr. Robert Aki, DPMLast medically reviewed: September 4, 2026
For many people with chronic joint pain, regenerative medicine offers a middle path between pain medication and joint replacement surgery. Whether it can help you depends on what is driving your pain, how much wear the joint has, and what you pair the treatment with. This guide explains what the evidence supports, what it does not, and what questions to bring to a consultation.
5
clinical providers on the team
22+ years
combined clinical experience
12+
treatments & services offered
What chronic joint pain usually involves
Chronic joint pain is most often driven by osteoarthritis, where cartilage wears down faster than it can repair itself, or by unresolved injuries that have left tendons, ligaments, or meniscus tissue damaged. In both cases the joint may also be inflamed, and the muscles around it are often weak, which makes pain worse and mobility harder.
What regenerative treatments target
Regenerative injections aim to support the tissue's own repair machinery: PRP delivers concentrated growth factors to an injured area, while cell-based therapy brings living cells into a damaged joint. Neither regenerates a joint overnight, and neither reverses end-stage arthritis, but both approaches are being studied, with mixed results, for improving pain and function in selected patients.
What the research actually shows
PRP for knee osteoarthritis is among the most-studied applications in the field, with systematic reviews reporting that many patients experience meaningful pain relief and improved function, though results vary and longer-term, high-quality trials are still limited. Cell-based approaches are earlier in their evidence base, built on smaller studies and ongoing trials. Honest providers translate this nuance for your specific joint rather than presenting either therapy as a guaranteed cure.
When it can help most
Mild to moderate osteoarthritis with reasonably intact joint alignment
Chronic tendon or ligament pain that has not settled with conservative care
Patients who are ready to pair treatment with strength work and activity modification
Earlier intervention, before cartilage loss becomes advanced
When it is less likely to help
End-stage arthritis with severe, advanced bone damage where surgery is likely needed
Joints that are unstable or significantly malaligned without correction
Cases where the primary problem is surgical, such as major tears that need repair
Situations where someone expects a guaranteed outcome or a cure
Frequently asked questions
How many treatments will I need? Many plans start with one evaluated treatment plus a rehabilitation program, though some patients benefit from follow-up injections months later. There is no fixed package.
Does the treatment hurt? The injection itself can be uncomfortable even after numbing, and the treated joint is often sore for a few days afterward. Most people manage well with the clinic's guidance.
Will it stop my arthritis from getting worse? Regenerative medicine is not proven to halt osteoarthritis progression. It is best understood as a way to support the joint and manage symptoms while you strengthen the support system around it.
What else should I be doing? Strength training, weight management, joint-friendly activity, and physical therapy often matter as much as the injection itself for chronic joint pain.
Chronic joint pain deserves a real evaluation, not a brochure. Bring your imaging, your history, and your questions to a consultation, and we will give you an honest read on whether regenerative medicine is likely to help. Call our team at (808) 593-2525.
Want to talk through your own situation?
Our team is happy to listen to your story, answer your questions, and help you decide
whether a consultation makes sense. There is no pressure and no obligation.
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.